Kangtai Biological's COVID-19 vaccine gets emergency use approval in China

BEIJING (Reuters) – China has given emergency use approval to a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products, the company said on Friday, adding a sixth shot to the country’s vaccination drive. China has already administered 366.9 million doses to people using five home-made products, three of which adopt a similar technology as the Kangtai shot, where inactivated coronavirus that cannot replicate in human cells is used to trigger an immune response. Kangtai did not say on Friday what sectors of China’s population its shot could be used in, when use would start or how long the approval will…